Bicycle Therapeutics (NASDAQ:BCYC) COO Alistair Milnes Sells 3,244 Shares

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) COO Alistair Milnes sold 3,244 shares of Bicycle Therapeutics stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $6.80, for a total transaction of $22,059.20. Following the completion of the sale, the chief operating officer owned 140,133 shares in the company, valued at $952,904.40. The trade was a 2.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Alistair Milnes also recently made the following trade(s):

• On Monday, January 5th, Alistair Milnes sold 3,416 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $6.46, for a total transaction of $22,067.36.

Bicycle Therapeutics Trading Down 0.6%

Shares of NASDAQ BCYC traded down $0.04 during mid-day trading on Tuesday, hitting $6.57. The company had a trading volume of 259,093 shares, compared to its average volume of 215,285. The firm has a 50-day simple moving average of $6.97 and a two-hundred day simple moving average of $7.42. The company has a market capitalization of $455.76 million, a PE ratio of -1.81 and a beta of 1.52. Bicycle Therapeutics PLC Sponsored ADR has a one year low of $6.03 and a one year high of $15.47.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, October 30th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.24. The business had revenue of $11.73 million for the quarter, compared to analyst estimates of $8.25 million. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%. Sell-side analysts expect that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on BCYC shares. Truist Financial assumed coverage on shares of Bicycle Therapeutics in a research note on Monday, November 24th. They issued a “hold” rating and a $10.00 target price for the company. JMP Securities set a $12.00 price target on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Royal Bank Of Canada restated a “sector perform” rating and set a $11.00 price objective (down from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Citigroup reaffirmed an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Seven equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Bicycle Therapeutics presently has an average rating of “Hold” and a consensus price target of $19.73.

Institutional Trading of Bicycle Therapeutics

Institutional investors have recently bought and sold shares of the business. Assetmark Inc. raised its position in shares of Bicycle Therapeutics by 74.9% in the third quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock valued at $28,000 after buying an additional 1,552 shares in the last quarter. Ausdal Financial Partners Inc. bought a new position in Bicycle Therapeutics during the 2nd quarter worth $70,000. Sei Investments Co. bought a new position in Bicycle Therapeutics during the 2nd quarter worth $74,000. Virtus Investment Advisers LLC raised its holdings in Bicycle Therapeutics by 32.6% in the 2nd quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock valued at $75,000 after acquiring an additional 2,659 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new stake in shares of Bicycle Therapeutics during the 2nd quarter valued at $86,000. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.